BCL2 and neoplasm: Low adiponectin levels may mediate the proliferation of ER- breast cancer cells by regulating genes involved in the cell cycle (such as p53, Bax, Bcl-2, c-myc and Cyclin D1) (101), which indicates that adiponectin can be used as adjuvant therapy for ER- breast cancer, and its local and systemic application can reduce tumor size and inhibit tumor metastasis.